Navigation Menu

Skip to Navigation menu Skip to top of page

06 May 2008

EPO revokes AstraZeneca’s pulmonary disease patent

Eklavya Gupte, London

One of AstraZeneca’s European patents covering Symbicort, a drug that treats pulmonary disease, has been revoked by the EPO following an appeal by generic manufacturers Norton Healthcare and Generics UK

The patent (EPB1014993) is one of two patents covering the Symbicort combination (formoterol and budesonide) used to treat chronic obstructive pulmonary disease.




The rest of this article is available to subscribers to Managing IP only.

Managing IP subscribers also have access to Managing Patents, Trade marks and Copyright until 30th October 2010.
Managing IP trialists have access to Managing Patents, Trade marks and Copyright for 48-hours.

Subscribe today for full access to this article. Alternatively, take a 48-hour free trial  giving you access to the current content. 

If you are already a subscriber please log in (see top right column) to access the rest of this article.